Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

101.60 +6.19 (+6.49%)

Streaming Delayed Price Updated: 1:33 PM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment ↗

May 12, 2023

Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of

Via Benzinga

Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm ↗

May 05, 2023

The company is targeting psoriasis with a first-ever mechanism that could rival leaders.

Via Investor's Business Daily

Protagonist Therapeutics: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

4 Analysts Have This to Say About Protagonist Therapeutics ↗

April 27, 2023

Via Benzinga

Why Shares of Protagonist Therapeutics Rose This Week ↗

April 20, 2023

The company's lead pipeline candidate is making news.

Via The Motley Fool

Why Protagonist Therapeutics Shares Are Nosediving ↗

April 05, 2023

Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 05, 2023

Via Benzinga

Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study ↗

March 15, 2023

Via Benzinga

Why Protagonist Therapeutics Shares Are Trading Higher Today ↗

March 07, 2023

Via Benzinga

Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock

April 04, 2023

Via ACCESSWIRE

Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

April 04, 2023

Via ACCESSWIRE

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023

Via ACCESSWIRE

Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera

March 15, 2023

Via ACCESSWIRE

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

April 26, 2022

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Via Benzinga

Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 07, 2023

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 07, 2023

Via Benzinga

Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday ↗

March 07, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Top 5 Health Care Stocks That May Collapse In February ↗

February 13, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Protagonist Therapeutics Earnings Perspective: Return On Capital Employed ↗

August 25, 2022

Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 05, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.

Via Benzinga

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing ↗

June 27, 2022

San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗

May 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗

May 22, 2022

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.

Via Benzinga

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years ↗

May 11, 2022

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Via InvestorPlace

Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet ↗

April 26, 2022

U.S. stocks remained lower toward the end of trading, with the Dow Jones tumbling more than 500 points on Tuesday.

Via Benzinga

71 Biggest Movers From Yesterday ↗

April 27, 2022

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.